{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rabeprazole+sodium+5+mg", "query": { "intervention": "Rabeprazole sodium 5 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rabeprazole+sodium+5+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T14:41:32.900Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02311946", "title": "A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Palbociclib Alone", "type": "DRUG" }, { "name": "Palbociclib + Rabeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2015-01", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2015-05-28", "last_synced_at": "2026-09-26T14:41:32.900Z", "location_count": 3, "location_summary": "Miami, Florida • South Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "South Miami", "state": "Florida" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02311946" }, { "nct_id": "NCT04510649", "title": "Surufatinib DDI With a PPI and a CYP3A Inducer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Part A", "type": "DRUG" }, { "name": "Part B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2020-07-09", "completion_date": "2021-03-02", "has_results": false, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-09-26T14:41:32.900Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510649" }, { "nct_id": "NCT00747526", "title": "A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroesophageal Reflux Disease (GERD)" ], "interventions": [ { "name": "Rabeprazole sodium 5 mg", "type": "DRUG" }, { "name": "Rabeprazole sodium 10 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "11 Months", "sex": "ALL", "summary": "1 Month to 11 Months" }, "enrollment_count": 51, "start_date": "2007-12", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2013-07-08", "last_synced_at": "2026-09-26T14:41:32.900Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Oakland, California • Washington D.C., District of Columbia + 10 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Maitland", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00747526" }, { "nct_id": "NCT07838987", "title": "A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "TERN-701", "type": "DRUG" }, { "name": "Rabeprazole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Pravastatin", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Bosentan", "type": "DRUG" }, { "name": "Quinidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 196, "start_date": "2023-12-21", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-26T14:41:32.900Z", "location_count": 1, "location_summary": "Millcreek, Utah", "locations": [ { "city": "Millcreek", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07838987" }, { "nct_id": "NCT04645940", "title": "Fruquintinib Food Effect and Proton Pump Inhibitor Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction", "Food-drug Interaction" ], "interventions": [ { "name": "fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole", "type": "DRUG" }, { "name": "fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 14, "start_date": "2020-09-24", "completion_date": "2020-11-18", "has_results": false, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-09-26T14:41:32.900Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04645940" }, { "nct_id": "NCT05918822", "title": "A Study of Maribavir Pediatric Formulation in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Maribavir Commercial Tablet Formulation", "type": "DRUG" }, { "name": "Maribavir Pediatric Powder-for-oral Suspension Formulation", "type": "DRUG" }, { "name": "Rabeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 32, "start_date": "2023-07-25", "completion_date": "2023-09-01", "has_results": true, "last_update_posted_date": "2024-09-26", "last_synced_at": "2026-09-26T14:41:32.900Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05918822" }, { "nct_id": "NCT01153659", "title": "A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "E3810", "type": "DRUG" }, { "name": "Aciphex (rabeprazole)", "type": "DRUG" }, { "name": "Nexium (esomeprazole)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 90, "start_date": "2010-07", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2013-11-01", "last_synced_at": "2026-09-26T14:41:32.900Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01153659" }, { "nct_id": "NCT00978016", "title": "A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Reflux Disease" ], "interventions": [ { "name": "arbaclofen placarbil-Cohort 1", "type": "DRUG" }, { "name": "Placebo-Cohort 5", "type": "DRUG" }, { "name": "arbaclofen placarbil-Cohort 2", "type": "DRUG" }, { "name": "arbaclofen placarbil-Cohort 3", "type": "DRUG" }, { "name": "arbaclofen placarbil-Cohort 4", "type": "DRUG" }, { "name": "PPI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XenoPort, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 460, "start_date": "2009-09", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-26T14:41:32.900Z", "location_count": 62, "location_summary": "Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00978016" }, { "nct_id": "NCT05446142", "title": "A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Encorafenib capsule formulation (CAP)", "type": "DRUG" }, { "name": "Encorafenib first formulation", "type": "DRUG" }, { "name": "Encorafenib second formulation", "type": "DRUG" }, { "name": "Rabeprazole tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-07-01", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2024-02-23", "last_synced_at": "2026-09-26T14:41:32.900Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05446142" }, { "nct_id": "NCT00992589", "title": "Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastroesophageal Reflux" ], "interventions": [ { "name": "Rabeprazole sodium 5 mg", "type": "DRUG" }, { "name": "Rabeprazole sodium 10 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "11 Months", "sex": "ALL", "summary": "1 Month to 11 Months" }, "enrollment_count": 344, "start_date": "2009-11", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2013-05-22", "last_synced_at": "2026-09-26T14:41:32.900Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Columbiana", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00992589" } ] }